CyclosporinThird Party Manufacturing in India

Cyclosporin works by binding intracellularly to cyclophilin, forming a complex that subsequently blocks calcineurin activity and prevents the dephosphorylation of the nuclear factor of activated T-cells (NFAT). This action effectively stops T-lymphocyte activation and downregulates inflammatory cytokines within the lacrimal apparatus. It acts on these immune pathways to help the body restore normal tear production and corneal health. Unlike basic artificial lubricants, it targets the root autoimmune cause of severe dry eye. It is highly effective and well-tolerated.

Therapeutic Uses

• Keratoconjunctivitis Sicca: Indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation.
• Chronic Ocular Surface Inflammation: Prescribed to treat persistent immunologically mediated damage to the corneal epithelium.

Why Manufacturers Choose Cyclosporin

Cyclosporin third party manufacturing in India represents a highly advanced, technologically intensive segment of the ophthalmic industry due to its complex oil-in-water nano-emulsion or clear solution configuration. Corporate buyers look for highly specialized manufacturing hubs to avoid stability failures. Celesta fulfills these rigorous requirements via sophisticated partner facilities that are WHO-GMP certified, utilizing advanced high-shear homogenization systems. Offering this high-tech molecule under WHO-GMP alignment establishes your brand as an advanced leader in specialized eye care.